Literature DB >> 2957330

Mechanism of action of the new immunomodulator LS2616 on T cell responses.

E L Larsson, A Joki, T Stålhandske.   

Abstract

Spleen cells from mice treated with LS2616 display a highly increased response to the polyclonal T cell lectin ConA. The total number of splenic T cells, and the relative ratios between L3T4+ and Lyt-2+ T cells were not altered by LS2616 treatment. By dissecting the overall ConA response it was found that the number of ConA-inducible, IL-2 reactive T cells was unaffected, while ConA-induced IL-2 production was enhanced after LS2616 treatment. Spleen cells from LS2616 treated mice, depleted of G10 adherent macrophages (M phi) and reconstituted with M phi from untreated mice displayed normal levels of ConA responses. M phi depleted spleen cells from untreated animals, cocultured with M phi enriched populations from LS2616 treated animals resulted in an increased ConA response. Furthermore, spleen cells from treated mice were found to be excellent stimulators for alloantigen-induced T cell responses; when used as responders in MLC, however, these cells were comparable to responders from non-treated animals. Taken together the results demonstrate that LS2616 exerts an immunostimulatory effect on M phi, which indirectly facilitates polyclonal and antigen-specific T cell responses. The possible implications of this observation on various immunoregulatory events are discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2957330     DOI: 10.1016/0192-0561(87)90016-6

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  15 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 2.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 3.  An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.

Authors:  W J Gradishar
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

4.  [Anti-angiogenesis: a new approach to tumor therapy?].

Authors:  D Schiefer; C Gottstein; V Diehl; A Engert
Journal:  Med Klin (Munich)       Date:  1999-10-15

5.  Effect of the synthetic immunomodulator, linomide, on experimental models of thyroiditis.

Authors:  P Hutchings; G Hedlund; K Dawe; S Howlett; A Cooke
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

6.  Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice.

Authors:  J Björk; S Kleinau
Journal:  Agents Actions       Date:  1989-06

Review 7.  Macrophage immunomodulation in chronic osteolytic diseases-the case of periodontitis.

Authors:  Corneliu Sima; Ana Viniegra; Michael Glogauer
Journal:  J Leukoc Biol       Date:  2018-11-19       Impact factor: 4.962

8.  Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug.

Authors:  D J Gross; H Sidi; L Weiss; T Kalland; E Rosenmann; S Slavin
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

9.  Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).

Authors:  D M Karussis; D Lehmann; S Slavin; U Vourka-Karussis; R Mizrachi-Koll; H Ovadia; T Kalland; O Abramsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

10.  Stimulation of wound healing by the immunomodulator LS-2616 (Linomide).

Authors:  J Lepistö; M Laato; J Niinikoski; C Lundberg; B Gerdin
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.